Kafix 200 LB Tablet is a combination pharmaceutical formulation containing Cefixime 200 mg, a third-generation cephalosporin antibiotic, and Lactobacillus spores equivalent to 2.5 billion viable organisms. Cefixime exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, making it effective against various gram-positive and gram-negative pathogens responsible for infections such as urinary tract infections, respiratory tract infections, otitis media, and uncomplicated gonorrhea. The inclusion of Lactobacillus spores serves as a probiotic adjunct to restore and maintain normal intestinal flora, which may be disrupted during antibiotic therapy, thereby reducing the risk of antibiotic-associated diarrhea and promoting gastrointestinal health. Kafix 200 LB is indicated for the treatment of susceptible bacterial infections where preservation of gut microbiota is clinically desirable. The combination ensures effective eradication of pathogens while minimizing gastrointestinal side effects commonly associated with antibiotic use. Dosage and duration should be determined by a healthcare professional based on the severity and type of infection. Patients should complete the full prescribed course to prevent resistance development. This medication is contraindicated in individuals with known hypersensitivity to cephalosporins or probiotics. Caution is advised in patients with a history of gastrointestinal disorders or immunocompromised states.